- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15.05. | Novartis, amid reorg, cuts 'select number' of biomedical research roles | ||
| 15.05. | Alumis pulls back from would-be rival to Amgen's Tepezza after assessing prospects | ||
| 15.05. | Aardvark to dig into phase 3 data early after FDA imposes hold | ||
| 14.05. | Create Medicines fashions $122M fundraise for in vivo CAR-T dreams | ||
| 14.05. | Biogen advances Alzheimer's tau program despite midphase miss | ||
| 14.05. | Regenxbio reaps pivotal win for Duchenne muscular dystrophy gene therapy | ||
| 14.05. | Aptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks development | ||
| 13.05. | With $1B Novo deal and diabetes ambitions undimmed, Lexicon is in 'good shape to go crazy' | ||
| 13.05. | Fosun pays $60M for option on AriBio's phase 3 Alzheimer's asset | ||
| 13.05. | Valneva to lay off up to 15% of workforce in face of 'adverse trend' in travel vaccines | ||
| 13.05. | Takeda 0 for 4 against nausea and vomiting after axing another asset | ||
| 12.05. | Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis | ||
| 12.05. | Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model | ||
| 12.05. | Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset | ||
| 12.05. | AstraZeneca's $800M bet undermined by immunogenicity in phase 3 | ||
| 12.05. | Bayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drug | ||
| 12.05. | Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China's R&D speed | ||
| 11.05. | Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data | ||
| 08.05. | Analysts cut enGene cancer sales forecast after updated data widen gap to J&J | ||
| 08.05. | Odyssey voyages to Nasdaq with $304M IPO to fund autoimmune, inflammatory pipeline | ||
| 07.05. | BeOne shelves 5 cancer programs, halts phase 2 rheumatoid arthritis trial | ||
| 07.05. | Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication | ||
| 07.05. | Ascendis axes IL-2 program in retreat from oncology expansion | ||
| 07.05. | Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis | ||
| 07.05. | From drug development to M&A, Big Pharmas showcase AI's 'measurable impact' |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.